Selective serotonin reuptake inhibitors: THREAD trial may show way forward.
作者信息
Peveler Robert, Kendrick Tony
出版信息
BMJ. 2005 Feb 19;330(7488):420-1. doi: 10.1136/bmj.330.7488.420-b.
Abstract
摘要
相似文献
1
Selective serotonin reuptake inhibitors: THREAD trial may show way forward.选择性5-羟色胺再摄取抑制剂：THREAD试验可能指明前进方向。
BMJ. 2005 Feb 19;330(7488):420-1. doi: 10.1136/bmj.330.7488.420-b.
2
Selective serotonin reuptake inhibitors: placebo washouts inflate antidepressant effects in general practice.选择性5-羟色胺再摄取抑制剂：在全科医疗中，安慰剂洗脱期夸大了抗抑郁药的疗效。
BMJ. 2005 Feb 19;330(7488):420. doi: 10.1136/bmj.330.7488.420-a.
3
Levomilnacipran (Fetzima) a new SNRI for depression.左旋米那普明（Fetzima），一种用于治疗抑郁症的新型5-羟色胺-去甲肾上腺素再摄取抑制剂。
Med Lett Drugs Ther. 2013 Dec 23;55(1432):101-2.
4
[Effectiveness of the new antidepressants compared with classic serotonin uptake inhibitors].新型抗抑郁药与经典血清素摄取抑制剂的疗效比较
Aten Primaria. 2006 Jun 15;38(1):5-7. doi: 10.1157/13090019.
5
Selective serotonin reuptake inhibitors: evidence base for older antidepressants is shaky too.选择性5-羟色胺再摄取抑制剂：老一代抗抑郁药的证据基础也不稳固。
BMJ. 2005 Feb 19;330(7488):420. doi: 10.1136/bmj.330.7488.420.
6
How have the SSRI antidepressants affected suicide risk?选择性5-羟色胺再摄取抑制剂（SSRI）类抗抑郁药对自杀风险有何影响？
Lancet. 2006 Jun 17;367(9527):1959-62. doi: 10.1016/S0140-6736(06)68860-0.
7
Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide?选择性5-羟色胺再摄取抑制剂是青少年自杀的一个风险因素吗？
Can J Psychiatry. 2009 Feb;54(2):69-71; discussion 76-7. doi: 10.1177/070674370905400201.
8
Treating major depression in children and adolescents: use of selective serotonin reuptake inhibitors needs urgent clarification.治疗儿童和青少年的重度抑郁症：选择性5-羟色胺再摄取抑制剂的使用亟需明确。
BMJ. 2004 Feb 28;328(7438):525. doi: 10.1136/bmj.328.7438.525-a.
9
Can the placebo be the cure?
Science. 1999 Apr 9;284(5412):238-40. doi: 10.1126/science.284.5412.238.
引用本文的文献
1
HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.HTR2A 与日本队列中重度抑郁症患者对 SSRI 的反应相关。
Neuromolecular Med. 2010 Sep;12(3):237-42. doi: 10.1007/s12017-009-8105-y. Epub 2009 Nov 24.
2
Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population.可能与日本女性重度抑郁症有关的转译因子 X 基因（TSNAX）。
Neuromolecular Med. 2010 Mar;12(1):78-85. doi: 10.1007/s12017-009-8090-1. Epub 2009 Sep 4.
3
CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients.生物钟基因（CLOCK）可能预测日本重度抑郁症患者对氟伏沙明治疗的反应。
Neuromolecular Med. 2009;11(2):53-7. doi: 10.1007/s12017-009-8060-7. Epub 2009 Apr 4.
4
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.度洛西汀每日一次60毫克用于治疗较轻的重度抑郁症。
Int J Clin Pract. 2006 May;60(5):613-20. doi: 10.1111/j.1368-5031.2006.00956.x.
本文引用的文献
1
Selective serotonin reuptake inhibitors.选择性5-羟色胺再摄取抑制剂
BMJ. 2004 Oct 9;329(7470):809-10. doi: 10.1136/bmj.329.7470.809.
2
Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.氟西汀用于轻度抑郁症急性治疗的随机安慰剂对照试验。
Am J Psychiatry. 2004 Oct;161(10):1864-71. doi: 10.1176/ajp.161.10.1864.
3
4
Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial.阿米替林治疗轻度抑郁症疗效的预测因素：一项全科医疗安慰剂对照试验
J Affect Disord. 1988 Jan-Feb;14(1):83-95. doi: 10.1016/0165-0327(88)90075-4.
Zotero 插件